Novo Nordisk Q2 Beat Fails to Calm Pricing Fears

What happened

Novo Nordisk reported Q2 earnings and revenue above consensus, driven by continued GLP-1 demand, particularly oral Wegovy. Despite the top-line beat, shares declined as management acknowledged ongoing pricing pressure in the U.S., with lower realized prices partially offsetting volume gains. The market also reacted to a cautious outlook, suggesting that the hoped-for stabilization in net pricing remains elusive. The results align with the existing DeepValue thesis that the next 6-12 months are dominated by price competition rather than prescription growth. Investors are now looking to the September Capital Markets Day for a clearer strategy on defending profitability.

Implication

Today's report confirms that volume growth remains robust, but the value per script continues to deteriorate, validating management's prior warnings. Without a clear inflection in net pricing, the stock is unlikely to re-rate from its current depressed multiples, even if headline sales beat. The upcoming Capital Markets Day on September 21 becomes the pivotal event; if management fails to outline a credible margin defense, the bear case strengthens. In the near term, we maintain our WAIT rating, with an attractive entry below $46, as the risk/reward remains skewed by uncertain U.S. economics. Position management should stay disciplined: add only if concrete evidence of pricing stabilization emerges or on a pullback to our downside support levels.

Thesis delta

The Q2 print does not alter our WAIT stance; it reinforces the view that volume is growing but pricing pressure is the dominant driver of returns. The catalyst path remains unchanged, with the September CMD as the next critical checkpoint for a potential thesis upgrade.